Which has better valuation and earnings, CYRX or ADAG?

CryoPort has higher revenue and earnings than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $176.18M 4.72 $78.30M $1.35 12.22 Adagene $7.67M 21.38 -$17.61M N/A N/A

Is CYRX or ADAG more profitable?

CryoPort has a net margin of 41.57% compared to Adagene's net margin of 0.00%. Adagene's return on equity of 0.00% beat CryoPort's return on equity. Company Net Margins Return on Equity Return on Assets CryoPort 41.57% -7.92% -4.79% Adagene N/A N/A N/A

Which has preferable valuation & earnings, ADAG or ALLO?

Adagene has higher revenue and earnings than Allogene Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 21.38 -$17.61M N/A N/A Allogene Therapeutics $20K 34,515.00 -$190.89M -$0.77 N/A

Is ADAG or ALLO more profitable?

Adagene's return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Allogene Therapeutics N/A -56.45% -40.36%

Which has stronger earnings and valuation, ADAG or DSGN?

Adagene has higher revenue and earnings than Design Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 21.38 -$17.61M N/A N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is ADAG or DSGN more profitable?

Adagene's return on equity of 0.00% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Design Therapeutics N/A -33.07% -31.29%

Which has higher earnings and valuation, ADAG or SLDB?

Adagene has higher revenue and earnings than Solid Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 21.38 -$17.61M N/A N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is ADAG or SLDB more profitable?

Adagene's return on equity of 0.00% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Solid Biosciences N/A -73.42% -61.13%

Do analysts rate AVTE or ADAG?

Adagene has a consensus price target of $8.00, indicating a potential upside of 131.21%. Given Adagene's stronger consensus rating and higher probable upside, analysts plainly believe Adagene is more favorable than Aerovate Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Adagene 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has higher valuation & earnings, AVTE or ADAG?

Adagene has higher revenue and earnings than Aerovate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A Adagene $7.67M 21.38 -$17.61M N/A N/A

Is AVTE or ADAG more profitable?

Adagene's return on equity of 0.00% beat Aerovate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aerovate Therapeutics N/A -90.19% -77.47% Adagene N/A N/A N/A

Adagene (ADAG) Competitors

$3.46 +0.07 (+2.06%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$3.46 0.00 (0.00%)

As of 06/3/2026 04:20 PM Eastern

Compare

ADAG vs. CYRX, ALLO, DSGN, SLDB, and AVTE

Should you buy Adagene stock or one of its competitors? MarketBeat compares Adagene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adagene include CryoPort (CYRX), Allogene Therapeutics (ALLO), Design Therapeutics (DSGN), Solid Biosciences (SLDB), and Aerovate Therapeutics (AVTE). These companies are all part of the "pharmaceutical products" industry.

How does Adagene compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Adagene (NASDAQ:ADAG) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

CryoPort has higher revenue and earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.72	$78.30M	$1.35	12.22
Adagene	$7.67M	21.38	-$17.61M	N/A	N/A

CryoPort has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Adagene has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

CryoPort currently has a consensus target price of $15.31, indicating a potential downside of 7.20%. Adagene has a consensus target price of $8.00, indicating a potential upside of 131.21%. Given Adagene's stronger consensus rating and higher possible upside, analysts plainly believe Adagene is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

CryoPort has a net margin of 41.57% compared to Adagene's net margin of 0.00%. Adagene's return on equity of 0.00% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Adagene	N/A	N/A	N/A

92.9% of CryoPort shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 10.0% of CryoPort shares are held by company insiders. Comparatively, 21.2% of Adagene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, CryoPort and CryoPort both had 1 articles in the media. CryoPort's average media sentiment score of 1.89 beat Adagene's score of 0.44 indicating that CryoPort is being referred to more favorably in the media.

Company	Overall Sentiment
CryoPort	Very Positive
Adagene	Neutral

Summary

CryoPort and Adagene tied by winning 7 of the 14 factors compared between the two stocks.

How does Adagene compare to Allogene Therapeutics?

Adagene (NASDAQ:ADAG) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

In the previous week, Allogene Therapeutics had 3 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Allogene Therapeutics and 1 mentions for Adagene. Allogene Therapeutics' average media sentiment score of 0.53 beat Adagene's score of 0.44 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adagene	Neutral
Allogene Therapeutics	Positive

Adagene presently has a consensus target price of $8.00, suggesting a potential upside of 131.21%. Allogene Therapeutics has a consensus target price of $8.52, suggesting a potential upside of 326.11%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

9.5% of Adagene shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Adagene has higher revenue and earnings than Allogene Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	21.38	-$17.61M	N/A	N/A
Allogene Therapeutics	$20K	34,515.00	-$190.89M	-$0.77	N/A

Adagene has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Adagene's return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Allogene Therapeutics	N/A	-56.45%	-40.36%

Summary

Adagene beats Allogene Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Adagene compare to Design Therapeutics?

Adagene (NASDAQ:ADAG) and Design Therapeutics (NASDAQ:DSGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability.

Adagene has a beta of 0.59, indicating that its share price is 41% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market.

Adagene's return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Design Therapeutics	N/A	-33.07%	-31.29%

Adagene currently has a consensus price target of $8.00, suggesting a potential upside of 131.21%. Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 58.05%. Given Adagene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Adagene is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Design Therapeutics had 1 more articles in the media than Adagene. MarketBeat recorded 2 mentions for Design Therapeutics and 1 mentions for Adagene. Design Therapeutics' average media sentiment score of 0.94 beat Adagene's score of 0.44 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Adagene	Neutral
Design Therapeutics	Positive

Adagene has higher revenue and earnings than Design Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	21.38	-$17.61M	N/A	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

9.5% of Adagene shares are held by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are held by institutional investors. 21.2% of Adagene shares are held by insiders. Comparatively, 17.1% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Adagene beats Design Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Adagene compare to Solid Biosciences?

Adagene (NASDAQ:ADAG) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Adagene's return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Solid Biosciences	N/A	-73.42%	-61.13%

In the previous week, Solid Biosciences had 3 more articles in the media than Adagene. MarketBeat recorded 4 mentions for Solid Biosciences and 1 mentions for Adagene. Solid Biosciences' average media sentiment score of 0.72 beat Adagene's score of 0.44 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Adagene	Neutral
Solid Biosciences	Positive

Adagene has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, suggesting that its stock price is 143% more volatile than the broader market.

Adagene has higher revenue and earnings than Solid Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	21.38	-$17.61M	N/A	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Adagene currently has a consensus price target of $8.00, suggesting a potential upside of 131.21%. Solid Biosciences has a consensus price target of $16.82, suggesting a potential upside of 145.52%. Given Solid Biosciences' higher possible upside, analysts clearly believe Solid Biosciences is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

9.5% of Adagene shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Adagene beats Solid Biosciences on 7 of the 13 factors compared between the two stocks.

How does Adagene compare to Aerovate Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Adagene's return on equity of 0.00% beat Aerovate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Adagene	N/A	N/A	N/A

Adagene has a consensus price target of $8.00, indicating a potential upside of 131.21%. Given Adagene's stronger consensus rating and higher probable upside, analysts plainly believe Adagene is more favorable than Aerovate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

9.5% of Adagene shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 21.2% of Adagene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Adagene had 1 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 1 mentions for Adagene and 0 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.67 beat Adagene's score of 0.44 indicating that Aerovate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aerovate Therapeutics	Positive
Adagene	Neutral

Adagene has higher revenue and earnings than Aerovate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Adagene	$7.67M	21.38	-$17.61M	N/A	N/A

Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Adagene has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Summary

Adagene beats Aerovate Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Adagene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADAG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADAG vs. The Competition

Export

Metric	Adagene	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$160.64M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	N/A	17.78	22.17	24.18
Price / Sales	21.38	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	4.61	6.63	9.84	6.72
Net Income	-$17.61M	$24.20M	$3.57B	$337.19M
7 Day Performance	-12.18%	-4.39%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	82.11%	45.50%	26.49%	33.10%

Adagene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADAG Adagene	2.0883 of 5 stars	$3.46 +2.1%	$8.00 +131.2%	+67.1%	$160.64M	$7.67M	N/A	260
CYRX CryoPort	3.6007 of 5 stars	$13.96 -0.3%	$14.69 +5.2%	+182.5%	$705.63M	$176.18M	10.34	1,186	Positive News Analyst Forecast
ALLO Allogene Therapeutics	2.5785 of 5 stars	$2.12 +6.0%	$8.52 +302.0%	+48.1%	$690.31M	N/A	N/A	310
DSGN Design Therapeutics	2.7635 of 5 stars	$11.40 +3.9%	$16.50 +44.7%	+160.3%	$685.15M	N/A	N/A	40
SLDB Solid Biosciences	2.7936 of 5 stars	$6.88 +3.9%	$16.36 +137.8%	+95.7%	$651.74M	N/A	N/A	100	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADAG) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adagene (ADAG) Competitors

ADAG vs. CYRX, ALLO, DSGN, SLDB, and AVTE

How does Adagene compare to CryoPort?

Summary

How does Adagene compare to Allogene Therapeutics?

Summary

How does Adagene compare to Design Therapeutics?

Summary

How does Adagene compare to Solid Biosciences?

Summary

How does Adagene compare to Aerovate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adagene (ADAG) Competitors

ADAG vs. CYRX, ALLO, DSGN, SLDB, and AVTE

How does Adagene compare to CryoPort?

Which has better valuation and earnings, CYRX or ADAG?

Which has more volatility and risk, CYRX or ADAG?

Do analysts prefer CYRX or ADAG?

Is CYRX or ADAG more profitable?

Do insiders and institutionals believe in CYRX or ADAG?

Does the media prefer CYRX or ADAG?

Summary

How does Adagene compare to Allogene Therapeutics?

Does the media favor ADAG or ALLO?

Do analysts recommend ADAG or ALLO?

Do institutionals and insiders hold more shares of ADAG or ALLO?

Which has preferable valuation & earnings, ADAG or ALLO?

Which has more volatility and risk, ADAG or ALLO?

Is ADAG or ALLO more profitable?

Summary

How does Adagene compare to Design Therapeutics?

Which has more volatility & risk, ADAG or DSGN?

Is ADAG or DSGN more profitable?

Do analysts recommend ADAG or DSGN?

Does the media favor ADAG or DSGN?

Which has stronger earnings and valuation, ADAG or DSGN?

Do insiders and institutionals hold more shares of ADAG or DSGN?

Summary

How does Adagene compare to Solid Biosciences?

Is ADAG or SLDB more profitable?

Does the media favor ADAG or SLDB?

Which has more risk and volatility, ADAG or SLDB?

Which has higher earnings and valuation, ADAG or SLDB?

Do analysts rate ADAG or SLDB?

Do institutionals and insiders hold more shares of ADAG or SLDB?

Summary

How does Adagene compare to Aerovate Therapeutics?

Is AVTE or ADAG more profitable?

Do analysts rate AVTE or ADAG?

Do insiders & institutionals believe in AVTE or ADAG?

Does the media prefer AVTE or ADAG?

Which has higher valuation & earnings, AVTE or ADAG?

Which has more risk & volatility, AVTE or ADAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAG vs. The Competition

Adagene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools